Literature DB >> 17154451

Spinal cord ependymomas.

J Brotchi1, G Fischer.   

Abstract

Ependymomas are the most frequent spinal cord tumors in adult patients. Although magnetic resonance imaging can be a highly accurate diagnostic tool, it does not always provide accurate differentiation between ependymomas and astrocytomas. This is why the authors recommend surgical resection and histological evaluation in all intraspinal cord tumors. It cannot be said that a tumor is unresectable without first attempting to remove it. Complete removal should be accomplished whenever possible, and patients should undergo operation before they become neurologically impaired. Quality of life depends on preoperative neurological status. Postoperative radiotherapy should be avoided in all low-grade ependymomas even after partial removal. Radiotherapy may be used to treat anaplastic ependymomas, which are quite rare in the spinal cord. Patients with low-grade ependymomas must be followed for years and undergo reoperation if necessary. In our experience treating 93 spinal cord ependymomas, complete removal was achieved in 86 patients and only one patient underwent reoperation 18 years later for tumor recurrence. The gold standard in treatment protocol is gross-total resection without adjunctive radiation therapy. Good long-term outcomes have been achieved by using this strategy.

Entities:  

Year:  1998        PMID: 17154451     DOI: 10.3171/foc.1998.4.5.5

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

1.  Outcome predictors in the management of spinal cord ependymoma.

Authors:  D Gavin Quigley; Naeem Farooqi; Timothy J D Pigott; Gordon F G Findlay; Robin Pillay; Neil Buxton; Michael D Jenkinson
Journal:  Eur Spine J       Date:  2006-07-25       Impact factor: 3.134

2.  Clinical characteristics and surgical outcomes of ependymomas in the upper cervical spinal cord: a single-center experience of 155 consecutive patients.

Authors:  Xiaobin Fei; Wenqing Jia; Heng Gao; Chenlong Yang; Da Li; Zenghui Qian; Bo Han; Dejiang Wang; Yulun Xu
Journal:  Neurosurg Rev       Date:  2020-08-07       Impact factor: 3.042

3.  Ependymomas.

Authors:  Sajeel Chowdhary; Myke R Green; Marc Chamberlain
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

4.  Spinal intradural, extramedullary anaplastic ependymoma with an extradural component: Case report and review of the literature.

Authors:  Kern H Guppy; Lewis Hou; Greg S Moes; Kamran Sahrakar
Journal:  Surg Neurol Int       Date:  2011-08-30

Review 5.  Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis.

Authors:  Dino Samartzis; Christopher C Gillis; Patrick Shih; John E O'Toole; Richard G Fessler
Journal:  Global Spine J       Date:  2015-03-31

6.  Surgical outcome and prognostic factors in spinal cord ependymoma: a single-center, long-term follow-up study.

Authors:  Oliver Gembruch; Mehdi Chihi; Merle Haarmann; Ahmet Parlak; Marvin Darkwah Oppong; Laurèl Rauschenbach; Anna Michel; Ramazan Jabbarli; Yahya Ahmadipour; Ulrich Sure; Philipp Dammann; Neriman Özkan
Journal:  Ther Adv Neurol Disord       Date:  2021-11-10       Impact factor: 6.570

7.  Complete Versus Incomplete Surgical Resection in Intramedullary Ependymomas: A Systematic Review and Meta-analysis.

Authors:  Farhad Salari; Mehdi Golpayegani; Mohsen Sadeghi-Naini; Sara Hanaei; Farhad Shokraneh; Ayat Ahmadi; Hamid Reza Khayat-Kashani; Alexander R Vacarro; Vafa Rahimi-Movaghar
Journal:  Global Spine J       Date:  2020-08-12

8.  Management and outcome in adult intramedullary spinal cord tumours: a 20-year single institution experience.

Authors:  Azize Boström; Nina-Christine Kanther; Alexander Grote; Jan Boström
Journal:  BMC Res Notes       Date:  2014-12-15

9.  Quality of life and return to work and sports after spinal ependymoma resection.

Authors:  Vicki M Butenschoen; Till Gloßner; Isabel C Hostettler; Bernhard Meyer; Maria Wostrack
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.